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Global alterations to the choroid plexus
blood-CSF barrier in amyotrophic lateral
sclerosis
J. Saul1,2, E. Hutchins3, R. Reiman3, M. Saul4, L. W. Ostrow5, B. T. Harris6, K. Van Keuren-Jensen3, R. Bowser1,2 and
N. Bakkar1,2*

Abstract
The choroid plexus (CP) is a highly vascularized structure located in the ventricles that forms the blood-CSF barrier (BCSFB)
and separates the blood from the cerebrospinal fluid (CSF). In addition to its role as a physical barrier, the CP functions in
CSF secretion, transport of nutrients into the central nervous system (CNS) and a gated point of entry of circulating
immune cells into the CNS. Aging and neurodegeneration have been reported to affect CP morphology and function and
increase protein leakage from blood to the CSF. Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease
associated with both upper and lower motor neuron loss, as well as altered proteomic and metabolomic signatures in the
CSF. The role of the BCSFB and the CP in ALS is unknown. Here we describe a transcriptomic and ultrastructural analysis of
BCSFB and CP alterations in human postmortem tissues from ALS and non-neurologic disease controls. ALS-CP exhibited
widespread disruptions in tight junctional components of the CP epithelial layer and vascular integrity. In addition, we
detected loss of pericytes around ALS blood vessels, accompanied by activation of platelet aggregation markers vWF and
Fibrinogen, reminiscent of vascular injury. To investigate the immune component of ALS-CP, we conducted a
comprehensive analysis of cytokines and chemokine panels in CP lysates and found a significant down-regulation of MCSF and V-CAM1 in ALS, as well as up-regulation of VEGF-A protein. This phenotype was accompanied by an infiltration of
MERTK positive macrophages into the parenchyma of the ALS-CP when compared to controls. Taken together, we
demonstrate widespread structural and functional disruptions of the BCSFB in human ALS increasing our understanding of
the disease pathology and identifying potential new targets for ALS therapeutic development.
Keywords: Choroid plexus, ALS, Blood-CSF barrier, RNA sequencing, Tight junctions

Introduction
The choroid plexus (CP) is a complex highly vascularized
structure comprised of a tight polarized epithelial cell
layer surrounding a stroma with highly fenestrated blood
vessels and forms the blood-CSF barrier (BCSFB) [29, 40,
59]. The CP is located inside of the four ventricles and
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functions in the active transepithelial transport of nutrients into the central nervous system (CNS) and the removal of metabolic by-products out of the CNS. CP
transcriptome analysis revealed that the choroid epithelium is a source of many growth factors that support the
proliferation of ventricular-subventricular zone (V-SVZ)
neural stem cells [67], and regulates the immune response
in inflammatory conditions [35]. Unlike the blood brain
barrier (BBB), the BCSFB is characterized by fenestrated
capillaries, with the real “barrier” function being performed by the CP epithelium. Adjacent CP epithelial cells
are bound by tight junctions that form the BCSFB,
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comprised of occludin, claudins 1–3 and 11 and zona occludens 1 (ZO-1). The CP is considered to be an active
immunomodulatory gate, as opposed to a passive inert
barrier [65], with M2 macrophages recruited to spinal
cord injury sites entering through the CP and trafficking
along the CSF to the injury site [66]. Healthy human CSF
is devoid of neutrophils, and is instead populated by
CD4+ memory T cells [41, 57] that enter the CSF through
Selectin and integrin-mediated adhesion to the CP. CSF
chemokine and leukocyte populations vary greatly under
normal and pathological conditions [49], highlighting the
dynamic interaction between the CP and the immune system, to support the continuous immunosurveillance and
response to disease and injury.
CP morphology and function change with normal aging
and neurodegenerative diseases such as Alzheimer’s disease (AD), including decreasing CSF production and turnover by as much as 50%, altering the levels of various
proteins and enzymes involved in energy production,
transport and free radical scavenging, but also increasing
protein leakage from blood to the CSF [63, 64]. In particular, AD exhibits decreased CP epithelial cell height compared to age-matched controls [64], and the increased
accumulation of Lipofuscin vacuoles and Biondi bodies
[74]. In addition, increased Aβ deposition in the CP, potentially via uptake from the CSF, has been observed in
AD [20, 73]. Increased deposition of Aβ oligomers in turn
activates CP matrix metalloproteinases (MMPs) which decreases occludin, E-cadherin and claudin levels and
thereby disrupt BCSF barrier integrity [11].
ALS is a fatal neurodegenerative disease that typically
leads to death within 2–5 years of diagnosis. ~ 90% of
the cases are considered sporadic, while 10% of ALS
cases are familial, with pathogenic gene mutations in ~
30 identified genes implicated in roughly 2/3rds of familial and 10% of sporadic cases [60, 79]. ALS is characterized by a progressive loss of upper and lower motor
neurons, leading to paralysis and eventual death. The
search of more effective therapies is hindered by the lack
of understanding of mechanisms contributing to disease
spread and motor neuron death. Potential mechanisms
of disease spread include direct anatomical connectivity
within the CNS [58] and recently proposed spread via
the CSF [68]. Multiple studies have shown BBB and
blood-spinal cord barrier (BSCB) impairments in human
ALS as well as the mutant SOD1 model of disease [26].
For example, IgG and C3/C4 complement deposits in
the spinal cord and motor cortex of ALS were first described by Donnenfeld and colleagues over 35 years ago
[21]. Endothelial cell degeneration, capillary leakage,
perivascular edema, tight junctional protein downregulation and microhemorrhages are other common signs of
barrier damage reported in ALS patients as well as ALS
mice models [25, 27, 32, 76]. Pericyte degeneration,

Page 2 of 21

perivascular basement membrane collagen IV expansion,
and white matter capillary abnormalities are significant
BBB-related pathologies in ALS patients that have not
been detected in animal models of ALS.
Our group, and others, have reported altered levels of
many proteins in CSF from ALS compared to controls,
including inflammatory proteins, as well as cytoskeletal
and extracellular matrix proteins, suggesting impaired
CP barrier permeability [8, 17, 61, 77]. ALS patient CSF
shows elevated total protein levels [30, 55], as well as increased CSF to serum ratios of albumin, IgG and complement C3 compared to non-neurological healthy
controls [1, 2, 9, 44], indicating a leakage from the blood
into the CSF and/or decreased clearance from the CSF.
More recently, Schwartz et al. described an impaired activation of the CP in the G93A SOD1 ALS mouse
model, possibly driven by decreased IFN-γ, leading to
impaired recruitment of CD4+ T cells into the CP and
the CSF [43]. In contrast to the mouse model, a recent
study described significantly increased levels of IFN-γ in
both CSF and serum of ALS patients [45], highlighting
the inherent differences in disease mechanisms between
human disease and SOD1 rodent models, and supporting
the need to examine the CP in the human disease.
Given the central role of the CP in CSF maintenance and
its function as an immune gatekeeper, we sought to investigate global transcriptomic and histopathological changes in
post-mortem CP of ALS and non-neurologic disease controls. We discovered global disruption of cellular adhesion
markers at the protein and mRNA levels in ALS-CP, as well
as vascular and pericyte disruptions. In addition, ALS-CP
exhibited marked activation and aggregation of platelets
and striking macrophage infiltration into the CP stroma, accompanied by increased VEGF-A protein and decreased
metalloproteinase levels. Taken together, our findings highlight disruption of the BCSFB structure and function as a
novel aspect of ALS pathogenesis.

Results
Global changes in CP ALS transcriptome

To evaluate the ALS-CP transcriptome, we performed
RNA sequencing (RNAseq) of the right lateral ventricles
of non-neurologic disease controls (n = 11), sporadic
ALS cases (n = 11) and C9-ALS (n = 3). Age did not differ between the control (average 65.3 + 12.7 years) and
the ALS groups (C9-ALS + SALS; average 66.6 + 10.8).
Two controls were statistically dropped out of the analysis due to their clustering discrepancy in PCA plots.
The C9-ALS group clustered with the SALS and so the
two groups were merged into one common ALS group.
Overall, there were 48 differentially expressed genes
(fold change > 2; p-adjusted < 0.05; average across all
samples> 20), with the majority of transcripts being
downregulated in ALS choroid plexus and only a
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minority of transcripts upregulated, a phenotype previously described in CP of subjects with major depressive
disorder ([72] volcano plot, Fig. 1a and heatmap Fig. 2).
Among differentially regulated genes were solute carrier
transmembrane transporters (SLC16A6 and SLCO2A1)
and cytoskeletal proteins protocadherin 1 (PCDH1) and
KANK3 (KN Motif And Ankyrin Repeat Domains 3).
Other differentially regulated genes were VEGF receptor
(Fms-related tyrosine kinase 4) Flt4, pericyte marker
CD13/ANPEP and platelet activation marker (Von Willebrand factor VWF).
We used ToppGene Suite to identify pathways enriched
in an enlarged dataset generated through relaxed analysis
parameters ([14]; Table 1). Results showed top pathways
enriched in ALS choroid plexus to be “NOTCH signaling”,
“endothelin signaling”, “platelet activation”, and “integrin
signaling”. All detected CP proteins were also classified
using Gene Ontology (GO) annotation. Figure 1b-c shows
the distribution of the identified proteins among the GOterms within the groups: molecular function, and biological process, using Panther. For molecular function
gene ontology, the proteins were predominantly enzymes,
molecule binding proteins, structural molecules, and
transporters. Biological processes altered in ALS-CP pertained to metabolic processes, localization, biological adhesion and immune regulation.
A further analysis of biological processes was then performed using multiple gene ontology analyses including
DAVID and ToppGene to avoid background annotation
bias and focus on commonalities (Table 2, and Supplemental Table 1). Common top biological processes altered in ALS-CP pertained to cellular adhesion,
vasculature/blood vessel development/VEGF signaling,
and platelet activation. It is noteworthy that some biological processes that were unique to the DAVID GO
analysis pertained to neuron projection and apoptosis,
acetylcholine receptor signaling, and chemotaxis potentially highlighting the role of the CP in regulation of
neuronal growth factors.
ALS alters BCSFB integrity

Given that cellular adhesion was among the top altered
biological processes in ALS-CP, and given the crucial
role for this layer as a barrier, we validated and further
explored tight junction and adhesion factors expressed
in the CP. We first performed a Q-PCR validation of
specific adhesion markers in a larger cohort of nonneurologic disease controls and ALS-CP samples
(Fig. 3a). We examined Claudin 1, Claudin 3, Claudin 5,
Occludin and ZO-1 in 31 ALS-CP samples compared to
15 non-neurologic disease controls. While Claudin 1,
Claudin 3, Occludin, and E-cadherin were significantly
downregulated (p-values of 0.0001, 0.0021, 0.007, and
0.0104, respectively), ZO-1 also reached significance (p-
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value of 0.0448), and Claudin 5 was not significantly altered (p-value of 0.1168). Interestingly, Claudin 5 transcript has recently been shown to be significantly
downregulated in FTD but not Huntington’s or Alzheimer’s disease choroid plexus [70].
To define the localization of adhesion markers in ALSCP, we focused on E-cadherin (Fig. 3b). In control CP,
E-cadherin specifically marks intercellular choroidal
junctions. In ALS-CP however, we observed a mislocalization of this marker, with many cases showing basal or
diffuse cytoplasmic localization of E-cadherin (blue arrows), while other cases show an overall absence from
intercellular junctions (red arrowheads). ZO-1 immunofluorescence showed a similar pattern of overall loss in
some ALS samples (Fig. S1, middle panel), while other
samples were characterized by regional losses of the adhesion marker (red arrowheads, Fig. S1). Additional adhesion markers examined, Claudin 5 showed regional
losses from endothelial cells in ALS CP (Fig. S2A, black
arrows). Additionally, we observed Claudin 5 staining in
nucleated cells located within blood vessel lumen in
most ALS cases (Fig. S2A, red arrowheads), although the
nature of these cells requires further investigations. Consistent with the lack of significant changes in Claudin 5
mRNA, protein levels of this adhesion marker were not
significantly altered in ALS by western blot analysis (Fig.
S2B). Both Claudin 3 and Occludin protein levels exhibited large variations within ALS samples, with some
showing down-regulation of the two markers (in samples
grouped as ALS cohort 1, Fig. S2B), while others were
characterized by no changes or even increases (samples
grouped as cohort 2, Fig. S2B). Taken together, these
findings support a global disruption of the BCSFB integrity in ALS-CP.
ALS activates platelet aggregation pathways

Since platelet activation was significantly altered in ALSCP by pathway analysis of the transcriptomic data, we
next examined markers of platelet activation in CP tissue. Platelets play a key role in hemostasis at sites of vascular injury where they rapidly bind damaged blood
vessel walls and aggregate to form a thrombus, thus preventing excessive bleeding [78]. Platelets also bind to
sites of endothelial cell erosion, stimulating thrombus
formation and promoting atherothrombotic disease [37].
Platelet adhesion to the extracellular matrix, followed by
release of the highly procoagulatory glycoprotein von
Willebrand factor (vWF) is the first step in the initiation
of the coagulation cascade. vWF is stored in endothelial
cell Weibel–Palade bodies (WPB), in α-granules of platelets, as well as in subendothelial connective tissue [54].
vWF in control CP showed a punctate staining pattern
typically associated with endothelial staining on the basal
side of CP epithelial cells, and virtually no or little vWF
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Fig. 1 a Volcano plot of significantly altered genes from the RNA-seq analysis on n = 11 non-neurological disease controls, n = 14 ALS cases (sporadic
and C9-ALS). The primary X axis shows the log2 (fold change) of controls vs ALS, while the secondary axis designates the −log10 (p value), analyzed
with the following parameters (adjusted p-values (p < 0.05), a fold change greater than 2, and a baseMean value greater than 20). The red dots mark
data points that are significantly altered in either direction. Relaxed analysis parameters were used for pathway analysis (adjusted p-values (p < 0.1), a
fold change greater than 1.5, and a baseMean value greater than 20) and pie graphs and tables visualizing the gene ontology (GO) distribution of
genes detected in both control and ALS groups classified by using Panther terms for biological processes b and molecular functions c
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Fig. 2 Heatmap of the Z-transformed regularized log gene expression values of top significantly altered genes, which highlights differences
between control and ALS (sporadic and C9-ALS). Upregulated genes are red, while downregulated genes are blue. Sample names are shown on
the bottom (CON vs SALS vs C9-ALS) while gene names are on the right. Case demographics can be found in the demographics table in the
supplemental materials

within blood vessel lumen (Fig. 4a and b, controls).
Some controls exhibited interstitial vWF punctate staining (2/6 controls, black arrowhead). Little vWF was evident in CP endothelial cells, with most staining located
to the basal side of CP epithelial cells. By contrast, in
ALS-CP, large vWF aggregates filled the lumen of blood
vessels and could be seen on the surface of platelets inside blood vessels (Fig. 4a and b), as well as inside endothelial cells (white arrowheads, Fig. 4a). We observed
clearly visible ultra-large vWF fibers (defined as vWF fibers ≥5 μm) typically associated with platelet adhesion
and aggregation in many ALS-CP vessels. Darker vWF
puncta, as well as larger aggregates were also observed
in the stroma surrounding blood vessels (red arrowheads, Fig. 4b), as well as inside the CP epithelial cells
(blue arrows, Fig. 4b).

Aside from vWF, platelet α-granules also contain adhesive glycoproteins such as P-selectin (CD62P) and fibrinogen as well as angiogenic factors, fibrinolytic inhibitors,
and various chemokines [78]. These factors play an important role in hemostasis but are also involved in modulating the immune response by releasing cytokines that
affect leukocyte function [36]. Fibrinogen cross-links
platelets and contributes to thrombus stabilization, while
P-selectin mediates the interactions between platelets, leukocytes, and endothelial cells, thereby regulating the release of proinflammatory cytokines. We investigated the
levels of fibrinogen and P-selectin in control and ALS-CP
tissues. While Fibrinogen was undetectable in control CP,
ALS CP demonstrated dark positive staining on endothelial surfaces, inside blood vessel lumens, and on the surface of platelets (Fig. 5a). A similar staining pattern was
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Table 2 Analysis of GO Biological processes using DAVID
GO Biological Processes

Count

%

PValue

Fold Enrichment

GO:0070208 ~ protein heterotrimerization

9

0.308325

1.54E-04

4.755443675

GO:0001501 ~ skeletal system development

35

1.199041

2.61E-04

1.889835686

GO:0007219 ~ Notch signaling pathway

30

1.027749

5.39E-04

1.92974526

GO:0007155 ~ cell adhesion

88

3.014731

5.77E-04

1.418229632

GO:0007507 ~ heart development

42

1.438849

6.58E-04

1.697754026

GO:0048010 ~ vascular endothelial growth factor receptor signaling pathway

21

0.719424

0.001052

2.157562408

GO:0061337 ~ cardiac conduction

15

0.513875

0.001791

2.465785609

GO:0007213 ~ G-protein coupled acetylcholine receptor signaling pathway

8

0.274066

0.00194

3.945256975

GO:0030168 ~ platelet activation

28

0.959233

0.002548

1.801095576

GO:0050921 ~ positive regulation of chemotaxis

7

0.239808

0.002691

4.315124816

GO:0010976 ~ positive regulation of neuron projection development

23

0.787941

0.003133

1.911676484

GO:0035556 ~ intracellular signal transduction

75

2.569373

0.003355

1.37667931

GO:0043525 ~ positive regulation of neuron apoptotic process

14

0.479616

0.00342

2.408441758

GO:0007569 ~ cell aging

10

0.342583

0.003925

2.958942731

GO:0048844 ~ artery morphogenesis

9

0.308325

0.004344

3.170295784

GO:0045333 ~ cellular respiration

9

0.308325

0.004344

3.170295784

GO:0033138 ~ positive regulation of peptidyl-serine phosphorylation

19

0.650908

0.004583

2.007853996

GO:0043547 ~ positive regulation of GTPase activity

99

3.391572

0.005103

1.296174028

GO:0003184 ~ pulmonary valve morphogenesis

6

0.20555

0.006259

4.438414097

GO:0003151 ~ outflow tract morphogenesis

14

0.479616

0.006454

2.251369469

observed for P-selectin, with both endothelial and luminal
vessels positive for this protein in ALS but not control CP
(Fig. 5b). To show that vWF aggregates were associated
with
platelet
adhesion
/aggregation,
we
coimmunolocalized vWF with P-selectin in control and ALSCP (Fig. 6, n = 3 controls, n = 6 ALS). We show again that
vWF is low in controls and limited to the basal side of CP
cells, while P-selectin could not be detected. ALS-CP
showed dramatic increases in overall vWF levels in the
stroma and sub-choroidal compartment as noted in Fig. 4
(Fig. 6, middle panel). Interestingly, lumenal vWF ultralarge aggregates were positive for P-selectin.
Taken together, these data support an activation of platelet
aggregation pathways, along with release of thrombusforming factors, presumably resulting from vascular damage.
Vascular integrity is compromised in ALS-CP

In order to further investigate the potential vascular
damage in ALS-CP, we focused on CD31, also known as
platelet endothelial cell adhesion molecule-1 (PECAM1), an endothelial cell marker that localizes to intercellular junctions, and plays an important role in endothelial
cell adhesion, but also implicated in T-cell homeostasis
and trafficking [46, 48, 56]. In control CP tissue, CD31
strongly labels endothelial cells with no staining in the
stroma or CP layer (arrows, Fig. 7a, n = 6). ALS-CP on
the other hand, exhibits global decreased levels of CD31,

but also a discontinuous punctate staining pattern in
some regions (Fig. 7a, arrowheads). It is unclear if this
decrease is specific for the CD31 protein or underlies an
actual loss of endothelial cells.
In an effort to link CD31 loss to vascular function, we
next focused on pericytes, “contractile” cells abundant in
the brain that modulate brain vessel permeability as part
of the neurovascular unit [3]. Since the CD13/ANPEP
pericyte marker transcript was significantly downregulated in the ALS-CP RNA-seq analysis (Fig. 2), we focused on ANPEP as well as another pericyte marker
PDGFRβ in ALS-CP compared to controls. Both pericyte
markers were detected in control CP, co-localized in the
same cells and surrounding blood vessel basement membrane marked with lectin (Fig. 8 and S3B, black arrows).
In ALS, varying degrees of pericyte loss were observed
and overall CD13/ANPEP signal was significantly downregulated (Fig. S3A and B red arrowheads). PDGFRβ signal failed to reach significance potentially due to high
variability within the control group (Fig. S3A). Some
blood vessels retained expression of both overlapping
markers (Fig. 8, middle panel, yellow arrowhead), while
other blood vessels had severe loss of both pericyte
markers CD13/ANPEP and PDGFRβ (white arrows,
middle panel). We also observed loss of PDGFRβ but
not CD13/ANPEP in some CP regions (Fig. 8, white arrowheads, right panel). Taken together, these findings
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Fig. 3 a RNA was extracted and quantitative real-time PCR analysis was performed on n = 15 controls and n = 31 SALS-CP tissues looking for
changes in tight junction and adhesion markers previously implicated in CP function/disease. Asterisks denote significance using Student t-test
and individual p-values are shown under the respective graphs. b Immunofluorescence for E-cadherin was performed on n = 3 controls and n = 5
ALS cases. Note the tight intercellular staining in controls, compared to missing or decreased staining from some CP cells (red arrowheads), or
diffuse cytoplasmic stain (blue arrows). DAPI was used to counterstain nuclei

support a loss of pericytes, potentially resulting in increased endothelial permeability, which coupled with the
severe loss of the CD31 endothelial marker highlights a
deregulation of BCSFB vascular integrity in ALS.
Immune activation in ALS-CP

Since the CP contains resident immune cells including T
cells and macrophages, we asked whether ALS alters the
immune cell composition of the CP. We investigated the
levels and localization of the macrophage markers Iba1
and MER Proto-Oncogene, Tyrosine Kinase (MERTK)
in ALS-CP and non-neurological disease controls. In
control CP, sparse Iba1 positive cells were located in the
choroidal stroma (arrowhead), and in close proximity to

the basal side of choroidal epithelia (arrows, Fig. 9a). A
marked increase in the number of Iba1 positive macrophages was observed in ALS cases in the stroma as well
as at the base of choroidal epithelial cells, with a highly
branched morphology (insert). It is noteworthy that we
rarely saw CD3 positive regulatory T cells (T reg) in
ALS choroid plexus (Supplementary Fig S4A).
MERTK expression is characteristic of immunosuppressive M2-like macrophages and contributes to clearance of apoptotic cells as well as platelet activation [13,
16]. In control CP, MERTK positive cells are located in
the choroid stroma, in close proximity to the basal side
of the choroidal epithelial cells (Fig. 9b, arrows and Fig.
S4B), similar to the Iba1 positive cells. The number of
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Fig. 4 a and b Immunohistochemistry for vWF was performed on n = 5 controls and n = 7 ALS cases. Pictures were taken under low
magnification to show the spread of positive staining throughout the tissue a and at 40x magnification b to show localization in the stroma (red
arrowheads), underneath the basal side of the choroid plexus epithelial layer (black arrows), and within CP cells (blue arrows). White arrowheads
point to staining within endothelial cells, while black arrowheads point to interstitial staining in some controls. Scale bar: 20 μm

these MERTK positive macrophages dramatically increases
in ALS-CP, with most cells similarly located on the stromal
side of the epithelial cells (Fig. 9b, arrows and supplemental
Fig. S4B for lower magnification). It is notable that we also
observed MERTK expression on the apical surface of some
choroidal cells in most ALS cases examined (Fig. 9b, inserts), although the significance of this expression within
the CP epithelial cells is unknown. In addition to dendritic
cells and macrophages, MERTK can be expressed by epithelial and endothelial cells [6], where it can drive

efferocytosis thus promoting wound healing as well as
down-regulation of pro-inflammatory signals.
To further define the immune signature in the ALSCP, we performed immunoassays on CP tissue lysates,
focusing on chemokines and cytokines that have previously been shown to be altered in ALS patients and the
SOD1G93A mouse model [43], as well as matrix metalloproteinases that have previously been implicated in
Alzheimer’s disease BCSFB breakdown [10, 11]. We used
44 ALS samples (including n = 7 C9-ALS and n = 36
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Fig. 5 a Immunohistochemical analysis of Fibrinogen staining in ALS (SALS and C9-AL) and controls. Pictures were taken at 40x magnification.
Scale bar: 20 μm. b Staining for P-selectin (CD62P) was performed in n = 4 control CP tissues, n = 10 SALS and n = 5 C9-ALS/C9-ALS-FTD cases

SALS) and 22 non-neurologic disease controls (Supplemental Table 2). Global results showed a large variability
within the ALS and the control group, with a subset of
each displaying an “inflammatory signature” (Fig. S5).
No correlations of the immune signature could be drawn
with patient gender, age, disease site of onset or disease
progression rates. Here again, and similar to our RNA-seq
transcriptomic analysis, CP samples harboring the c9orf72
repeat expansion did not differ from SALS-CP samples
(Figs. S5 and S6). Out of the analytes examined, 6 showed
significant changes between the two groups (Figs. 10a and
S5), and two additional trended toward significance (Fracktalkine/CX3CL1 and VCAM-1; Fig. 10b). All three examined metalloproteinases (MMP1, MMP3 and MMP9) were
surprisingly downregulated in ALS compared to controls.
M-CSF and V-CAM1 were also downregulated in ALS
compared to controls, while VEGF-A was significantly increased in the ALS group (Fig. 10).
A subset of ALS-CP samples showed increased Creactive protein (CRP) compared to controls (Fig. S5).

CRP is an acute inflammatory protein synthesized primarily in liver hepatocytes but also by smooth muscle
cells, macrophages, endothelial cells, lymphocytes, and
adipocytes [69]. CRP plays an active role in the inflammatory process, activating C1q in the complement pathway and depositing in tissues at sites of
tissue damage. We examined the localization of CRP
in ALS-CP compared to neurological (AD) and nonneurological disease controls. No CRP immunostaining was found in control CP or AD CP. However,
ALS-CP had notable increases in CRP immunostaining in 8 of 11 cases (Fig. 11). Intense CRP signal was
detected on the inner endothelial walls in most CRP
positive ALS cases (red arrowheads), as well as within
the blood vessel lumen (possibly on the surface of
platelets). We observed some CRP positive signal in
the stroma of 3 out of the 8 CRP positive cases examined (yellow arrowhead). In addition, choroid epithelial cells also contained CRP immunoreactivity in
some ALS cases (blue arrows).
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Fig. 6 Immunofluorescence for vWF and P-selectin was performed on n=6 ALS and n=3 control CP tissues and imaged under 63x using confocal
microscopy. Lectin was used to mark blood vessels and DAPI denotes nuclei. DIC (differential interference contrast) images were taken to show
tissue morphology. Scale bar: 10um

Discussion
Although prior studies have explored the BBB/BSCB in
ALS, to date none have investigated the BCSFB in human ALS. In the present study, we investigated BCSFB
integrity in postmortem CP tissue from patients with
ALS and non-neurological controls. We find alterations
and/or reductions in expression levels of multiple tight
junction and adhesion markers in ALS-CP compared to
controls, including Claudin 1 and 3, Occludin and E-

cadherin. Interestingly, Claudin 5 which has previously
been shown to be down-regulated in medulla and cervical but not lumbar ALS patient spinal cord [25] was
not significantly altered in ALS-CP at the mRNA or protein levels. In addition, and similarly to previous reports
on ALS BBB/BSCB, we observed down-regulation and
discontinuous CD31 expression in endothelial cells in
ALS-CP, indicating possible endothelial barrier breakage
at the BCSFB (Fig. 7 and [25]). We also report
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Fig. 7 Immunohistological characterization of CD31 staining in n = 10 ALS and n = 6 control CP tissue samples. Black arrows point to continuous
staining on the surface of endothelial cells, while black arrowheads highlight areas of discontinuous staining

reductions in pericyte numbers around blood vessels in
ALS-CP as determined by expression of CD13/ANPEP
and PDGFR-β, a phenotype akin to reported pericyte
losses in the BSCB in ALS (Figs. 8, S3 and [76]). A dysfunction/damage of the structural elements of the
BCSFB (the CP epithelium, the endothelial cells and surrounding pericytes) that typically form a tightly integrated unit regulating access and flow to and from the
CNS may contribute to a toxic CNS environment.
Indeed, pericyte losses have been correlated with increased BSCB damage measured by extravascular
hemoglobin deposition in human ALS, [76], but also increased BBB permeability to water and large and small
molecular weight tracers in mice [4, 18]. In a mouse
model of Alzheimer’s disease, pericyte loss increased immunoglobulin G (IgG) extravascular deposition, decreased microvasculature density/capillary length, and
increased Aβ deposition and pathology [62]. In the
SOD1 ALS mouse model, human pericyte injection extended survival of male mice and activated the host antioxidant response [15]. Pericyte loss is thought to affect
brain vessel permeability by modulating endothelial
transcytosis as well as deregulating molecular pathways
in endothelial cells [3]. Very little is known about the
role of pericytes in the CP, although they have been
shown to support endothelial cell formation during development [53]. Interestingly, one of the genes deregulated in pericyte-deficient endothelial cells is VEGFA
[18, 75]. VEGF-A is upregulated in pericyte-deficient
states, potentially inducing a disruption of inter-

endothelial junctions and increased extracellular matrix
(ECM) degradation in endothelial cells, thereby opening
the junctional barrier [22, 50].
Interestingly, and consistent with the state of pericyte
loss we report, VEGF-A protein is significantly upregulated in ALS-CP samples compared to controls (Fig. 10a).
Macrophages have been shown to release large amounts
of VEGF-A and affect vascular permeability [39] and
MERTK signaling similarly regulates endothelial function and angiogenesis [24, 33]. Both MERTK levels and
macrophages along with VEGF-A protein are increased
in ALS-CP tissues compared to controls. VEGF-A was
previously found to be significantly elevated in serum
and CSF of ALS patient [31], but clinical trials boosting
VEGF-A levels in ALS patients have failed. Given the effect of VEGF-A on increasing vascular permeability at
the various blood-brain and BCSFBs, one can speculate
that boosting VEGF-A levels has detrimental effects on
BCSFB integrity, thus exacerbating disease pathogenesis.
Increased cytokine levels and decreased tight junction expression at the BBB and BCSF have previously been correlated [5, 12, 42]. In fact, prior studies have shown that
endothelial cells exposed to inflammatory cytokines exhibit
reduced CD31 expression in intercellular junctions, which
enhances T-cell activation [46]. In ALS-CP, we find widespread CD31 loss and a subset of ALS-CP tissues with a
high inflammatory signature, as measured by higher levels
of IL-6, IL-8, Thrombomodulin and P-Selectin (Fig. 10).
These cytokines and chemokines were measured in whole
CP tissue lysates that included multiple cell types making
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Fig. 8 Immunofluorescence staining for pericyte markers CD13/ANPEP and PDGFR-β was performed on control and ALS-CP tissues. Slides were
imaged under 63x using confocal microscopy. Lectin was used to mark blood vessel and DAPI stains nuclei. White arrows point to blood vessel
with no staining for either pericyte marker, while white arrowheads show loss of one of the marker. Yellow arrows show ALS blood vessels with
spared pericytes. Scale bar: 10um

the sensitivity of the immunoassays really low, potentially
diluting local increases in these cytokines in particular cellular subtypes. It is noteworthy that neither the RNA-seq
analysis, nor the immunoassay protein expression data or
the immunohistochemical analysis showed remarkable
differences between SALS and C9-ALS, suggesting that
BCSFB defects are a general mechanism of ALS pathogenesis. We detected few to no dipeptide repeat element proteins (DPRs) (measured by poly GA and poly GP staining)
in C9-ALS-CP, and few phospho-TDP43 inclusions, only in
the choroidal stroma of 2/12 ALS cases (Fig. S4C and data
not shown).

Interestingly, and in contrast to AD models where
BCSFB disruptions induced by Aβ oligomers were mediated by MMP3 [11], we observed significant downregulation of all MMP proteins examined (MMP1, 3 and 9) in
ALS-CP. MMP9 has previously been shown to be both
upregulated [23] and downregulated [52] in CSF of ALS
patients, and two studies found it to be increased in ALS
serum [7, 19]. MMP1 was unaltered in ALS CSF [52]. It is
notable that we did not detect RNA transcripts for either
of these MMPs in the RNA-seq in ALS or control tissues,
suggesting that the transcriptional source of these proteases is not the CP itself. Nevertheless, the low level of
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Fig. 9 Immunohistochemical analysis for macrophage markers Iba-1 a and MERTK b in control and ALS-CP postmortem tissues. Arrows in a and
b point to macrophage localization at the base of the CP epithelial cells, while arrowheads in a point to stromal localization.Insert in a shows a
highly branched morphology of an Iba1-positive cell. Arrowheads in b point to apical MERTK staining on the surface of CP epithelial cells, while
inserts in b highlight staining on the apical surface of CP cells. Scale bars: 20 μm

these MMPs in CP may result from impaired balance between the proteases and their inhibitors (TIMPs) and/or
their increased degradation/ clearance. Further studies are
needed to investigate this observation.
Disruptions in the BCSFB in an ALS mouse model
were accompanied by a lack of activation of IFN-γ signaling and a lack of leukocyte trafficking into the CSF
and spinal cord [43]. We were unable to detect IFN- γ
mRNA in ALS or control tissues and IFN-γ protein was
very low/below detection limit in multiple ALS and control samples, although a subset of ALS cases had lower
IFN-γ than controls (not reaching statistical significance). Additional inflammatory markers downregulated
in the mouse at late disease stages included ICAM-1,
CCL2 and Fractalkine. MCP-1/CCL2 and Fractalkine
showed a similar trend in ALS-CP tissues, but failed to
reach statistical significance. Other notable differences

with the SOD1 mouse model include a near absence of
T-cells in the CP of either ALS or control groups, although we did observe an accumulation of MERTK
positive and Iba1 positive macrophages in ALS-CP. Such
differences could be attributed to inherent differences in
signaling at the CP level between mice and human, or
due to the overexpression of mutant human SOD1 in
the transgenic mouse model when compared to sporadic
human ALS. In fact, in one ALS patient harboring an
SOD1 mutation (N139K), both IFN-γ and ICAM-1 were
down-regulated, but Fractalkine was increased (Fig. S5).
Nevertheless, the lack of an immune activation response
supporting leukocyte trafficking in the CP of the
SOD1G93A ALS mouse model [43] is consistent with
our human ALS-CP data where we observed significant
downregulation of the M-CSF cytokine and the VCAM1 leukocyte transendothelial migration marker.
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Fig. 10 a Protein levels of various chemokines and metalloproteinases were measured by MesoScale Discovery assays, and results for n = 44 ALS
and n = 22 controls CP samples were log-transformed and plotted. p-values were calculated through a logistic regression model that accounts for
patient age (under 65 vs above 65), as well as the plate on which the sample was run to avoid batch effect bias. Graphs shown are for analytes
with significant p-values≤0.05 (also denoted by red asterisks). b Analysis performed similar to a and analytes represented had p-values close to
significance (exact values depicted on the figure). Raw data can be found in table S2
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Fig. 11 CRP immunohistochemical analysis of ALS and CON CP cases. Red arrowheads point to CRP deposition on luminal side of blood vessels,
blue arrows point to CRP inside select CP epithelial cells in ALS, while yellow arrowheads point to stromal CRP staining. Scale bar: 20 μm

An interesting finding in ALS-CP is the induction of
platelet activation markers in ALS-CP, shown at the gene
expression level from the RNA-seq data and vWF, Fibrinogen and P-selectin immunostaining. Taken together,
these indicate a severe underlying vascular injury in CP
blood vessels, accompanied by activation of clotting factors. Deposition of vWF and Fibrinogen along inner endothelial walls in ALS but not control CP, along with vWF
expression on platelets surface, support this hypothesis
(Figs. 4 and 5). No circulating endothelial cells in peripheral blood have been previously detected in moderate or
late stage ALS (as defined by ALSFRS measures) [28], suggesting that endothelial damage in ALS is accompanied by
repair, presumably through clotting rather than detachment of dysfunctional endothelial cells. It is noteworthy
that vWF mRNA was significantly downregulated in ALSCP, while vWF protein was increased in those tissues suggesting that the source of this factor is not the CP tissue
itself, but rather packaged storage α-granules in platelets.
CRP has previously been detected in serum and CSF
of ALS patients and its elevation in plasma shown to
correlate with faster disease progression [47, 61]. In line
with these findings, we have observed higher CRP levels
in ALS cases with a higher immune signature as well as
higher SAA levels (Fig. S5). Interestingly, at the histological level, we also observed increased CRP levels in
the choroid stroma as well as in some CP cells (Fig. 11,

blue arrows). This may reflect CRP protein in transit
from the plasma compartment towards the CSF through
the CP epithelial cells, but it is also possible that CRP itself is expressed by choroidal cells. We also observed a
novel accumulation of CRP on the CP endothelial walls
of ALS but not control or AD tissues, a phenotype
highly reminiscent of atherosclerotic plaques (Fig. 11,
red arrowheads). CRP is known to localize directly to
atherosclerotic plaques where it induces the expression
of genes directly involved in monocytes adhesion, recruitment of intracellular molecules such as E-selectin
and activating the complement system [69]. Further
study is needed to investigate the nature of the CRP aggregates in ALS-CP.
A cohort of ALS CP samples exhibited an “inflammatory signature” in the protein immunoassay panels (Fig.
S5) characterized by elevated levels of multiple cytokines
and immunokines, suggesting the existence of a subtype
of ALS patients with increased inflammation. This phenotype is highly reminiscent of recent findings in postmortem ALS cortex that described distinct molecular subtypes
of ALS, with 19% of assayed cortex samples showing signatures of activated glia and immune cells [71].
Taken together, we hereby describe significant alterations in the BCSFB in ALS, with a disruption of the junctions in the CP epithelial cells, and activation of platelets
and immune infiltration into the CP, as well as major
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vascular disruptions and degradation associated with the
disease. Further studies are required to examine markers
of CP trans-epithelial transport as well as pathways
involved in the metabolic function of these highly
energy-consuming cells. Nevertheless, our findings
pave the way towards a deeper understanding of the
BCSFB involvement and disruption in ALS, and given
the CP’s role as one of the drug delivery routes into
the CNS could prove highly useful for therapy development and delivery.

Methods
Tissue samples

ALS and non-neurologic disease control post-mortem
choroid plexus tissue samples were obtained from the
Barrow Neurological Institute ALS Tissue Bank, the Target ALS Human Postmortem Tissue Core and the NIH
Neurobiobank. All tissues samples were collected after
informed consent from the subjects or by the subjects’
next of kin, complying with all relevant ethical regulations. The postmortem tissue bank protocol and consent
process were approved by the Dignity Health Institutional Review Board, and both the Target ALS and NIH
Neurobiobank use IRB approved protocols and consents
to collect and distribute tissue samples for research purposes. Clinical diagnoses were made by board certified
neuropathologists according to consensus criteria for
ALS. Subject demographics are listed in Suppl. Table 3.
Bioinformatic methods

Demultiplexing and fastq generation were performed
using CASAVA v1.8.4 (Illumina), followed by trimming
of 7 nt from both R1 and R2 using cutadapt v1.10, as
recommended in the SMARTer manual. Reads were
then aligned to the GRCh37 human genome using STAR
v2.5.2b, and raw counts were calculated with featureCounts (subread v1.5.1) using the ensembl75 annotation.
Analysis and differential expression testing were performed in R using DESeq2 v1.14.1, with batch, sex, and
age (< 65 or > 65 years) accounted for in the design. Differentially expressed genes were selected based on the
following criteria: adjusted p-values (p < 0.05), a fold
change greater than 2, and a baseMean value greater
than 20. Heatmaps were generated using the pheatmap
v1.0.8 R package, using Z-transformed values on the rlog transformed expression from DESeq2, after batch
correction in limma for flowcell run. For the relaxed
parameter analysis, we used: adjusted p-values (p < 0.1),
a fold change greater than 1.5, and a base Mean value
greater than 20.
Gene ontology analysis for biological processes and
pathways enriched in the dataset was performed using
ToppGene Suite using FDR correction and a cutoff of 0.05
[14]. P-values were generated using the “Hypergeometric
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probability mass function”. Biological processes analysis
was also performed using DAVID Bioinformatics Resources 6.8 [34]. Gene annotation ontology for biological
processes and molecular functions was performed using
PANTHER (Protein ANalysis THrough Evolutionary Relationships) Classification System version 14 [51].
Choroid plexus protein lysate preparation

Fresh frozen tissue was obtained from the Target ALS
Postmortem Tissue Core and NIH NeuroBioBank. Frozen tissue was placed into ice-cold lysis buffer (20 mM
Tris, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA,
1% Triton X-100, with 100 uL Phosphatase Inhibitor
Cocktail Set II (Sigma) and 100 uL Protease Inhibitor
Cocktail (Sigma) added per 10 mL lysis buffer), at an approximate ratio of 67 uL lysis buffer per 10 mg tissue.
Lysates were prepared in three batches as tissue was acquired. Tissue was homogenized mechanically with
OmniTip probes for hard tissue (Omni International),
for 10 s each at low, medium, and high speed. Homogenates were transferred to 1.5 mL microcentrifuge tubes
and sonicated in an ice-cold water bath three times for
30 s at 40% amplitude. Samples were rotated at 4 °C for
30 min, and centrifuged at 4 °C for 10 min at 20,000 x g.
Supernatant was collected and stored at − 80 °C. Lysate
total protein concentration was determined by Bradford
assay (Bio-Rad). These lysates were used for western blot
analysis using the Invitrogen NuPAGE Bis-Tris protein
gels, transferred onto PVDF membranes and probed
with primary and secondary antibodies (1:15,000 dilution; LiCor). Signals were imaged by using the Odyssey
CLx imager (LiCor).
Meso scale discovery immunoassay analysis

Twenty-one markers were measured using the following
Mesoscale Discovery kits: Human Vascular Injury I Kit,
V-PLEX Vascular Injury Panel 2 Human Kit, V-PLEX
Human Proinflammatory Panel II + IFN-γ, Human
MMP 3-Plex Ultra-Sensitive Kit, and a custom U-PLEX
panel for M-CSF, IL-4, MCP-1, Fractalkine, and VEGFA. Manufacturer instructions were followed for each kit.
All samples were bound to plates overnight at 4 °C with
vigorous agitation on a MicroMix 5 plate shaker (DPC).
Lysates were diluted in the recommended diluent provided with each kit. Of the 21 markers, IL-4 had 65% of
the samples below detection limit and ICAM-3 signal
was very low and close to background, so neither analyte
was included in further analysis.
RNA extraction and Q-PCR

Total RNA were prepared from frozen tissue from control and ALS cases. Samples were homogenized in Trizol
(Invitrogen), and RNA was extracted using the Ambion
PureLink™ RNA Mini Kit. RNA quality was determined
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by RIN (RNA integrity number) using a Tapestation (see
Table S4 for RIN values for samples used for RNA-seq).
cDNA was synthesized using Superscript VILO (Invitrogen) and real-time RT-PCR was performed using the
FastStart Universal SyberGreen master mix (Roche).
RNA-seq library preparation

Isolated RNA concentrations were measured with QuantiT Ribogreen RNA Assay (Thermo Fisher, Cat. No.:
R11490). For each RNA sample, 100–200 ng total RNA
was ribodepleted with Illumina’s Ribo-Zero Gold rRNA
Removal Kit (Illumina, Cat. No. MRZG12324) and purified with NucleoSpin RNA XS columns (Machery Nagel,
Cat. No. 740902.10) according to Takara Bio’s “Protocol
for Removal of rRNA from Small Amounts of Total
RNA.” Double-stranded cDNA was synthesized from the
ribodepleted RNA using the SMARTer Universal Low Input RNA Kit for Sequencing (Takara Bio, Cat. No.
634940) with a 16-cycle PCR. The concentration of cDNA
was measured with Qubit dsDNA HS Reagent (ThermoFisher Scientific, Cat. No. Q32854). Double-stranded
cDNA (3.6 - 14 ng) was fragmented with the Covaris E220
(Peak Incident Power = 140 W, Duty Factory = 10%, Cycles/Burst = 200, Treatment Time = 80 s). The fragmented
cDNA was then prepared into libraries using KAPA Hyper
Prep Kit (KAPA Biosystems, Cat. No. KK8504). This library preparation included a combination end repair & Atailing reaction, followed by a 4 °C overnight ligation of
uniquely barcoded adapters to each sample at a 200:1
adapter to insert molar ratio and a 7-cycle enrichment
PCR. The size of each final library was determined by
TapeStation (Agilent High Sensitivity D1000 ScreenTape
& Sample Buffer, Cat. No. 5067–5584 & Cat. No. 5067–
5603), and the concentration was measured with KAPA
SYBR FAST Universal qPCR Kit (KAPA Biosystems, Cat.
No. KK4824). Libraries were then combined into equimolar pools which were also measured for size and concentration. The pools were clustered onto a paired-end
flowcell (Illumina, Cat. No. PE-401-3001) with a 20% v/v
PhiX v3 spike-in (Illumina, Cat. No. FC-110-3001) and sequenced on Illumina’s HiSeq 2500 with TruSeq SBS Kit
v3-HS chemistry (Illumina, Cat. No. FC-401-3002) to 30
million read pairs per library. The first and second reads
were each 83 bases.
IHC and immunofluorescence

Paraffin-embedded post-mortem tissue sections from
choroid plexus were used for this study. All sections
were deparaffinized, rehydrated and antigen retrieval
performed using Target Antigen Retrieval Solution, pH
9.0 (DAKO) or a citrate buffer (pH 6) for 20 min in a
steamer. After cooling to room temperature, nonspecific binding sites were blocked using Super Block
(Scytek), supplemented with Avidin (Vector Labs).
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Primary antibodies used for immunohistochemistry were
incubated overnight in Super Block with Biotin (antibodies listed in Suppl. Table 5). Slides were then washed
and incubated for 1 h in the appropriate biotinylated IgG
secondary antibodies (1:200; Vector Labs) in Super
Block. Slides were washed in PBS and immunostaining
visualized using the Vectastain Elite ABC reagent (Vector Labs) and Vector Immpact NovaRED peroxidase
substrate kit (Vector Labs). Slides were counterstained
with hematoxylin (Sigma Aldrich).
For immunofluorescence, paraffin sections were deparaffinized, rehydrates and antigen retrieval was performed
in appropriate buffers. Sections were blocked in Super
Block (Scytek) and primary antibodies were incubated
overnight in Antibody Diluent, background reducing
(Dako). Slides were then washed in PBS and incubated
in Alexafluor-conjugated secondary antibodies, prepared
in the same antibody diluent for 1 h at room
temperature. Following washes, autofluorescence was
decreased using the autofluorescence eliminator (Millipore) for 5 min, and slides were rinsed in 70% ethanol
before mounting using Vectashield antifade mounting
media with DAPI (Vector labs). Signal intensity was
quantified using Imaris and signal intensity was normalized to tissue section volume.
Statistical analysis

Choroid lysates for the MSD analysis were prepared in
three batches, with variable ratios of ALS cases to controls
in each batch. To adjust for batch effect, individual
markers were compared between ALS and controls,
adjusting for batch effects using a likelihood ratio test of
deviance. A parent model was fit using logistic regression
to predict case/control status from plate number. An extended model was then fit to predict the disease case/control status from the plate number plus the marker of
interest. The deviance between the nested models were
compared using a likelihood ratio test. P-values indicate
the significance of a marker’s contributes to the prediction
of case/control status after adjusting for plate number. To
generate the MSD heat maps, the ComBat R script was
used to adjust for batch effect for all markers collectively
[38]. Then Z-values across all samples were computed as
(value-average/standard deviation).

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s40478-020-00968-9.
Additional file 1: Figure S1. ZO-1 immunofluorescence was performed
on control (n = 4) and ALS CP (n = 5) and staining was imaged under 20x
using confocal microscopy. DAPI denotes nuclei and DIC (differential
interference contrast) images were taken to show tissue morphology.
Scale bar: 50um. Red arrowheads point to areas of loss of ZO-1 staining
in between CP epithelial cells. Figure S2. A) Immunohistochemistry for
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Claudin 5 was performed on control (n = 3) and ALS CP (n = 5). Pictures
were taken at 40X magnification. Scale bar: 20 μm. Black Arrows point to
staining in endothelial cells and red arrowheads point to staining within
the lumen of blood vessels. B) Western blot analysis was performed on 9
controls and 18 SALS CP lysates and membranes were probed for Claudin 3 and 5, as well as Occludin. GAPDH was used as a loading control.
Figure S3. A) Quantification of immunofluorescence signal intensity for
CD13 and PDGFRbeta on n = 3 control and n = 5 ALS CP samples was
performed using Imaris. Image stacks were taken at 63x magnification
and ten different Z-stack fields per sample were captured and quantified.
Tissues boundaries were delineated and signal intensity was normalized
to section volume. The asterisk denotes significance with a p-value of
0.0095. Values for PDGFRbeta were not found to be significant. B) CD13/
ANPEP immunohistochemistry in ALS (n = 5) and control (n = 4) CP. Black
arrows point to CD13 stain around blood vessels on controls and red arrowheads denote vascular areas of CD13 loss in ALS. Figure S4 A) CD3
staining in ALS-CP tissues. Scale bar: 20 μm. B) MERTK immunohistochemistry in ALS and Control CP. Pictures were taken at low magnification to
show extent of MERTK expression. Scale bar 100 μm C) p-TDP43 (S409/
410) staining in CP from ALS and Control postmortem tissues. Only two
ALS cases showed any inclusions, and these were located in the choroid
stroma. Scale bar: 20 μm. Figure S5 Heatmap showing Z-scores across all
samples for all gene targets that had reliable MSD signal. Samples are
presented in their respective groups (control vs ALS), ranked by cumulative sum of all analytes measured. Figure S6 All cytokines and chemokines analyzed by MSD immunoassays in n = 22 controls and n = 44 ALSCP lysates. None of the shown analytes showed significant differences
between the two groups through a logistic regression analysis that accounts for patient age (under 65 vs above 65), as well as the plate on
which the sample was run to avoid batch effect bias. Both IFN-γ and
TNF-α had low signal to background ratio. Supplemental Table 1.
ToppGene Analysis showing the top 30 enriched Biological Processes.
Supplemental Table 2. MSD immunoassay analysis of CP lysates from
ALS and non-neurological disease controls. Supplemental Table 3.
Demographics for post-mortem tissue samples. Supplemental Table 4.
CP samples used for RNA-seq. Supplemental Table 5. List of antibodies
used in analysis of CP samples.
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